Market Brief: Bharat Biotech IPO Outlook Bharat Biotech International Ltd, the Hyderabad-based pioneer behind India’s indigenous Covid-19 vaccine, is actively exploring an initial public offering (IPO) targeted to raise upwards of **$500 million**. The move comes as the company seeks to capitalize on its global prominence, having delivered more than **9 billion** vaccine doses worldwide since its inception in **1996**. While the promoter family currently holds **100%** equity, this potential listing would mark a significant transition toward public transparency and market-driven valuation. Financial Performance & Growth Recent financial data indicates a strengthening bottom line. The company's revenue rose to **₹1,462.9 crore** in **FY25**, up from **₹1,323.2 crore** the previous year. More impressively, operating profit margins saw a sharp ascent to **28.2%** in **FY25**, compared to just **8.8%** in **FY24**. This growth is supported by a diversified portfolio. While the oral polio vaccine was historically the primary revenue driver, the company has successfully shifted focus toward higher-volume products like its Typhoid Conjugate (TCV), Rotavirus (RV), and Japanese Encephalitis (JE) vaccines. Strategic Infrastructure To bolster future capacity, Bharat Biotech is investing heavily in its Sapigen Biologix facility in Bhubaneswar. The project involves a capital expenditure of **₹200–250 crore** for **FY26**, aimed at creating a large-scale manufacturing hub. The start of production at this plant is expected to optimize the company's working capital, which saw inventory days spike to **340** in **FY25** due to supply chain build-outs. Sector Dynamics The Indian pharmaceutical market is entering **2026** with strong fundamentals, projecting a growth rate between **7.8% and 8.1%**. This momentum is supported by the federal "Biopharma Shakti" initiative, which has earmarked **₹10,000 crore** over the next five years to boost domestic production of biologics and biosimilars. As a key supplier to the Government of India and UNICEF, Bharat Biotech remains central to institutional procurement, though it continues to navigate the volatility of tender-based pricing and increasing competition in export markets. IPO Market Context The primary market for new share sales in India has seen a selective start in **2026**. Investors are currently prioritizing volume-driven growth and sustainable earnings over pandemic-era peaks. If it proceeds, Bharat Biotech’s **$500 million** offering would serve as a major bellwether for the biotechnology sector, joining a high-profile pipeline that includes major players like Jio Platforms and the National Stock Exchange. Proceeds from the sale are expected to fund further R&D and next-generation vaccine platforms.